

Supplemental Material to:

Marco Donia, Paolo Fagone, Ferdinando Nicoletti, Rikke Sick Andersen, Estrid Høgdall, Per Thor Straten, Mads Hald Andersen and Inge Marie Svane

BRAF inhibition improves tumor recognition by the immune system:

Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer


Oncoimmunology 2012; 1(9)

<http://dx.doi.org/10.4161/onci.21940>

<http://www.landesbioscience.com/journals/oncoimmunology/article/21940/>

Supplementary Figures

Supplementary Figure S1



Sensitivity of short-term cultured melanoma cell lines to vem. Short-term cultured melanoma cell lines were seeded into 24 well plates and, after 24 hours, various concentrations of vem were added. Growth inhibition was evaluated after 72 hours of incubation. Pt. : patient

Supplementary Tables

Supplementary Table S2. Full list of TAAs known to be immunogenic in melanoma

MART-2	AIM-2	TRP-1 / gp75
NY-ESO-1 /		
LAGE-2	BAGE-1	MAGE-A6
MAGE-A1	Bcl-2	OA1
MAGE-A10	Bcl-xL	TAG
MAGE-A12	beta-catenin	TAG-1
MAGE-A2	BING-4	Telomerase
MAGE-A3	B-RAF	SSX-2
MAGE-A4	BRAF600	TRAG-3
707-AP	Livin (ML-IAP)	TRG
LAGE-1	CDKN2A	survivin-2B
MAGE-C2	MAGE-A9	SNRPD1
IDO1	cyclin B1	Survivin
MC1R	CYP1B1	TRP-2
Melan-A /	DAM-6, -10 (MAGE-B1,	
MART-1	-B2)	TRP2-6b
Meloe-1	XBP-1	TRP2-INT2
Meloe-2	p15	tyrosinase
MG50	EFTUD2	RhoC
MUM-1	EphA2	OS-9
MUM-2	GAGE-1,2,8	RAB38 / NY-MEL-1
MUM-3	GnTV	PRDX5
N-ras	gp100 / Pmel17	PRAME
MAGE-A8	HERV-K-MEL	P Polypeptide
CML28 (EXOSC5)	CDK4	

Supplementary Table S3. Full list of the “MHCI-restricted antigen processing and presentation pathway” genes

TAPBP	HLA-G
B2M	NFYA
CREB1	NFYB
Canx	nfyc
CALR	PSME1
Hspa11	PSME2
HSPA1A	PSME3
HSPA1B	PDIA3
Hspa2	TAP1
HSPA4	TAP2
HSPA6	
HSPA7	
HSPA8	
HSP90AA1	
HSP90AA2	
HSP90AB1	
HSPA5	
ifi30	
LGMN	
Ita	
HLA-A	
HLA-E	
HLA-F	